Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1704 - Correlation between programmed death-ligand 1 (PD-L1) expression and T790M status in EGFR-mutant non-small cell lung cancer (NSCLC)


08 Oct 2016


Poster Display


Akito Hata


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


A. Hata1, N. Katakami1, S. Nanjo1, C. Okuda2, R. Kaji2, K. Masago2, S. Fujita2, Y. Imai3

Author affiliations

  • 1 Division Of Integrated Oncology, Institute of Biomedical Research and Innovation, 650-0047 - Kobe/JP
  • 2 Integrated Oncology, Institute of Biomedical Research and Innovation, 650-0047 - Kobe/JP
  • 3 Department Of Pathology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP


Abstract 1704


Correlation between PD-L1 expression and T790M status is unclear. Therapeutic interventions could affect PD-L1 expression, and rebiopsied fresh samples may be desirable to analyze PD-L1 expression.


We retrospectively analyzed PD-L1 expression and T790M status in rebiopsied samples of EGFR-mutant NSCLC after acquired resistance. PD-L1 immunohistochemistry was performed using the SP142 anti-PD-L1 antibody for tumor cell membrane staining. H-score was adopted to evaluate both percentage and intensity, and scores ≥1 were defined as PD-L1 + , and scores ≥10 as strong PD-L1+. T790M status was examined using the PNA-LNA PCR clamp or cycleave method. Survival analyses were done according to PD-L1 and T790M status at first rebiopsy.


We investigated 63 available rebiopsied histologic samples in 45 patients. Median H-score in T790M+ (n = 25) samples was 0 (range, 0-6), whereas T790M- (n = 38) was 1 (range, 0-91) (Wilcoxon, p = 0.0451). PD-L1+ was confirmed in 12 (48%) of 25 T790M+ samples, and in 28 (74%) of 38 T790M- (p = 0.0383). Strong PD-L1+ was identified in 0 (0%) T790M + , but in 3 (8%) T790M- (p = 0.1500). Ten patients received multiple rebiopsies. In 7 of these 10 patients, T790M status had changed from T790M+ to T790M-. Among 4 of these 7, PD-L1 expression also changed from PD-L1- to PD-L1 + , in accordance with T790M status from T790M+ to T790M-. Median overall survival (OS) of PD-L1+ (n = 30) vs. PD-L1- (n = 15) were 55.0 months vs. not reached months, respectively (p = 0.1071). Median OS of T790M+ (n = 16) vs. T790M- (n = 29) were 80.3 vs. 55.0 months, respectively (p = 0.1340).


T790M+ status was correlated to lower PD-L1 expression. Conversely, T790M- status was associated with higher PD-L1 expression, suggesting a potential efficacy of anti-PD-1/PD-L1 immunotherapies for T790M- population. PD-L1 expression might have a prognostic value, even in EGFR-mutant NSCLC.

Clinical trial identification

Legal entity responsible for the study



Foundation for Biomedical Research and Innovation


A. Hata: Akito Hata received lecture fee from Chugai, Astra Zeneca, Boehringer Ingelheim, and Eli Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings